A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure.
A novel vaccine against porcine parvovirus (PPV), composed of recombinant virus-like particles (PPV-VLPs) produced with the baculovirus expression vector system (BEVS) at industrial scale, was tested for its immunogenicity and protective potency. A formulation of submicrogram amounts of PPV-VLPs in a water-in-mineral oil adjuvant evoked high serum antibody titres in both guinea pigs, used as reference model, and target species, pigs. A single immunisation with 0.7microg of this antigen yielded complete foetal protection against PPV infection after challenge with a virulent strain of this virus. Furthermore, also in the presence of mild adjuvants the protective action of these PPV-VLPs is excellent. This recombinant subunit vaccine overcomes some of the drawbacks of classical PPV vaccines.
Antonis
Adriaan F G
AF
Animal Sciences Group (ASG, Previously ID-Lelystad), P.O. Box 65, 8200 AB Lelystad, The Netherlands.
Bruschke
Christianne J M
CJ
Rueda
Paloma
P
Maranga
Luis
L
Casal
J Ignacio
JI
Vela
Carmen
C
Hilgers
Luuk A Th
LA
Belt
Peter B G M
PB
Weerdmeester
Klaas
K
Carrondo
Manuel J T
MJ
Langeveld
Jan P M
JP
D000276:Adjuvants, Immunologic; D000818:Animals; D004305:Dose-Response Relationship, Drug; D005260:Female; D006168:Guinea Pigs; D010322:Parvoviridae Infections / Q000517:prevention & control / Q000662:veterinary*; D028323:Parvovirus, Porcine / Q000276:immunology*; D011247:Pregnancy; D013552:Swine; D013553:Swine Diseases / Q000517:prevention & control*; D014765:Viral Vaccines / Q000009:adverse effects / Q000276:immunology*
D000276:Adjuvants, Immunologic; D014765:Viral Vaccines